AstraZeneca plans to invest a whopping $3.5 billion to expand its R&D and manufacturing operations in the US by 2026, as part of a drive to raise its revenues to $80 billion by the end of the decade. The programme will include the construction of a new R&D centre at Kendall Square in the heart of the biopharma hub in Cambridge, Massachusetts, and a biologics manufacturing facility in Maryland. There will also be expansion of cell therapy manufacturing capacity on "the West and East coasts," as well as specialty manufacturing in Texas. Source: Pharmaphorum 12/11/2024